Influenza (avian and other zoonotic)

    Overview

    Animal influenza viruses are distinct from human seasonal influenza viruses and do not easily transmit between humans. However, zoonotic influenza viruses - animal influenza viruses that may occasionally infect humans through direct or indirect contact - can cause disease in humans ranging from a mild illness to death.

    Birds are the natural hosts for avian influenza viruses. After an outbreak of A(H5N1) virus in 1997 in poultry in Hong Kong SAR, China, since 2003, this avian and other influenza viruses have spread from Asia to Europe and Africa. In 2013, human infections with the influenza A(H7N9) virus were reported in China.

    Most swine influenza viruses do not cause disease in humans, but some countries have reported cases of human infection from certain swine influenza viruses. Close proximity to infected pigs or visiting locations where pigs are exhibited has been reported for most human cases, but some limited human-to-human transmission has occurred.

    Just like birds and pigs, other animals such as horses and dogs, can be infected with their own influenza viruses (canine influenza viruses, equine influenza viruses, etc.).

    Symptoms

    Avian, swine and other zoonotic influenza infections in humans may cause disease ranging from mild upper respiratory infection (fever and cough) to rapid progression to severe pneumonia, acute respiratory distress syndrome, shock and even death.

    Gastrointestinal symptoms such as nausea, vomiting and diarrhea has been reported more frequently in A(H5N1) infection. Conjunctivitis has also been reported in influenza A(H7).

    Disease features such as the incubation period, severity of symptoms and clinical outcome varies by the virus causing infection but mainly manifests with respiratory symptoms.

    Treatment

    Evidence suggests that some antiviral drugs, notably neuraminidase inhibitor (oseltamivir, zanamivir), can reduce the duration of viral replication and improve prospects of survival, however ongoing clinical studies are needed. Emergence of oseltamivir resistance has been reported.

    News

    All →

    Publications

    All →
    Pandemic influenza preparedness framework: partnership contribution high-level implementation plan III 2024-2030 

    The Pandemic Influenza Preparedness (PIP) Framework's Partnership Contribution (PC) High-Level Implementation Plan III (HLIP III) outlines the...

    Pandemic influenza preparedness framework: progress report, 1 January - 30 June 2022

    The Pandemic Influenza Preparedness (PIP) Framework is a World Health Assembly resolution adopted unanimously by all Member States in 2011. It brings together...

    WHO consultation to adapt influenza sentinel surveillance systems to include COVID-19 virological surveillance: virtual meeting, 6 – 8 October 2020

    Sentinel surveillance for influenza and COVID-19 is a resource-effective approach to gathering critical information about both viral infections in patients...

    Integrated sentinel surveillance of influenza and SARS-CoV-2 and the development of the Global Influenza Surveillance and Response System Plus: virtual meeting, 12 – 14 October 2021

    The first WHO consultation from 6 – 8 October 2020 developed interim guidance of epidemiological and laboratory surveillance of influenza and SARS-CoV-2...

    Videos

    All →